Source:http://linkedlifedata.com/resource/pubmed/id/10482937
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1999-10-25
|
| pubmed:abstractText |
We evaluated the response and toxicity of rituximab in the setting of progressive intermediate grade non-Hodgkin's lymphoma (NHL) after autologous peripheral stem cell transplantation (PSCT). Seven patients with a median age of 59 years (45-62), ECOG performance status 0-1, and CD20-positive diffuse large cell lymphoma with progression after PSCT were treated. All patients initially received 4-weekly infusions of rituximab (375 mg/m2). The maximum response was three CR and four PR. Median progression-free survival was 197 days (range 60-282). With a median follow-up of 204 (115-299) days, the patients' disease status is classified as two CR, one PR, and four PD. Four of five patients with ECOG performance status of 1 prior to treatment showed improvement to status 0 after treatment with rituximab. While follow-up is short, these results suggest that rituximab has significant activity in intermediate-grade non-Hodgkin's lymphoma that has relapsed after PSCT.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
24
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
521-6
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:10482937-Antibodies, Monoclonal,
pubmed-meshheading:10482937-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:10482937-Antigens, CD20,
pubmed-meshheading:10482937-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10482937-B-Lymphocytes,
pubmed-meshheading:10482937-Combined Modality Therapy,
pubmed-meshheading:10482937-Disease-Free Survival,
pubmed-meshheading:10482937-Female,
pubmed-meshheading:10482937-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:10482937-Humans,
pubmed-meshheading:10482937-Immunization, Passive,
pubmed-meshheading:10482937-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:10482937-Lymphoma, Non-Hodgkin,
pubmed-meshheading:10482937-Male,
pubmed-meshheading:10482937-Middle Aged,
pubmed-meshheading:10482937-Salvage Therapy,
pubmed-meshheading:10482937-Transplantation, Autologous,
pubmed-meshheading:10482937-Treatment Outcome
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation.
|
| pubmed:affiliation |
Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA.
|
| pubmed:publicationType |
Journal Article
|